CytRx PE Ratio 2010-2022 | CYTR
Current and historical p/e ratio for CytRx (CYTR) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. CytRx PE ratio as of May 27, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
CytRx PE Ratio Historical Data |
Date |
Stock Price |
TTM Net EPS |
PE Ratio |
2019-06-03 |
0.31 |
|
0.00 |
2019-06-30 |
0.31 |
$-0.18 |
0.00 |
2019-03-31 |
0.66 |
$-0.24 |
0.00 |
2018-12-31 |
0.45 |
$-0.35 |
0.00 |
2018-09-30 |
1.05 |
$-0.51 |
0.00 |
2018-06-30 |
1.13 |
$-0.60 |
0.00 |
2018-03-31 |
1.59 |
$-1.10 |
0.00 |
2017-12-31 |
1.69 |
$-1.55 |
0.00 |
2017-09-30 |
2.46 |
$-1.75 |
0.00 |
2017-06-30 |
3.76 |
$-2.34 |
0.00 |
2017-03-31 |
2.67 |
$-3.36 |
0.00 |
2016-12-31 |
2.23 |
$-3.90 |
0.00 |
2016-09-30 |
3.53 |
$-5.64 |
0.00 |
2016-06-30 |
13.38 |
$-5.52 |
0.00 |
2016-03-31 |
16.08 |
$-5.16 |
0.00 |
2015-12-31 |
15.90 |
$-5.88 |
0.00 |
2015-09-30 |
14.22 |
$-5.22 |
0.00 |
2015-06-30 |
22.32 |
$-5.16 |
0.00 |
2015-03-31 |
20.22 |
$-5.58 |
0.00 |
2014-12-31 |
16.44 |
$-3.24 |
0.00 |
2014-09-30 |
15.24 |
$-6.42 |
0.00 |
2014-06-30 |
25.08 |
$-7.80 |
0.00 |
2014-03-31 |
20.94 |
$-6.78 |
0.00 |
2013-12-31 |
37.62 |
$-8.64 |
0.00 |
2013-09-30 |
19.38 |
$-2.52 |
0.00 |
2013-06-30 |
12.00 |
$-0.12 |
0.00 |
2013-03-31 |
16.32 |
$-3.24 |
0.00 |
2012-12-31 |
11.22 |
$-4.80 |
0.00 |
2012-09-30 |
21.78 |
$-7.56 |
0.00 |
2012-06-30 |
27.48 |
$-7.98 |
0.00 |
2012-03-31 |
16.81 |
$-5.46 |
0.00 |
2011-12-31 |
11.76 |
$-5.04 |
0.00 |
2011-09-30 |
14.15 |
$-1.68 |
0.00 |
2011-06-30 |
30.24 |
$-3.36 |
0.00 |
2011-03-31 |
36.96 |
$-1.68 |
0.00 |
2010-12-31 |
42.42 |
$0.42 |
101.05 |
2010-09-30 |
31.50 |
$-2.94 |
0.00 |
2010-06-30 |
32.34 |
$0.42 |
77.04 |
2010-03-31 |
46.62 |
$-0.84 |
0.00 |
2009-12-31 |
47.04 |
$-2.10 |
0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
|